The National Institute for Health and Care Excellence (NICE) has refused the 'miracle' drugs lecanemab and donanemab for use ...

Part of the law also means that some Alzheimer's patients won't have to go through step therapy, a process of using a less ...

Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for b ...

BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the interim safety review of the clinical Phase 2a study EXIST ...

Reimagining Alzheimer's care in Canada is not just important for the system—it is imperative for all Canadians. We owe it to those affected to provide the dignity and quality of life they deserve. The ...

The Lantern at Morning Pointe Alzheimer’s Center of Excellence, Chattanooga is hosting “Moments of Grace: A Memory Caregiver ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $190.82, a high estimate of ...

Two new drugs targeting early-stage Alzheimer’s disease are expected to be put into clinical use as soon as Thursday next ...

A new Fujirebio Diagnostics blood test identifies beta-amyloid, a brain plaque that is a key marker for Alzheimer’s disease.

A Chinese company that developed the country’s first indigenous therapy for Alzheimer’s disease has suspended production and ...

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

Content by Health System. June is Alzheimer’s and Brain Awareness Month, which means there’s no better time to focus on your ...